1
|
Ovdiichuk O, Lahdenpohja S, Béen Q, Tanguy L, Kuhnast B, Collet-Defossez C. [ 18F]fluoride Activation and 18F-Labelling in Hydrous Conditions-Towards a Microfluidic Synthesis of PET Radiopharmaceuticals. Molecules 2023; 29:147. [PMID: 38202730 PMCID: PMC10779751 DOI: 10.3390/molecules29010147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 12/15/2023] [Accepted: 12/20/2023] [Indexed: 01/12/2024] Open
Abstract
18F-labelled radiopharmaceuticals are indispensable in positron emission tomography. The critical step in the preparation of 18F-labelled tracers is the anhydrous F-18 nucleophilic substitution reaction, which involves [18F]F- anions generated in aqueous media by the cyclotron. For this, azeotropic drying by distillation is widely used in standard synthesisers, but microfluidic systems are often not compatible with such a process. To avoid this step, several methods compatible with aqueous media have been developed. We summarised the existing approaches and two of them have been studied in detail. [18F]fluoride elution efficiencies have been investigated under different conditions showing high 18F-recovery. Finally, a large scope of precursors has been assessed for radiochemical conversion, and these hydrous labelling techniques have shown their potential for tracer production using a microfluidic approach, more particularly compatible with iMiDEV™ cassette volumes.
Collapse
Affiliation(s)
- Olga Ovdiichuk
- Nancyclotep, Molecular Imaging Platform, 54500 Vandoeuvre-les-Nancy, France
| | - Salla Lahdenpohja
- Université Paris Saclay, CEA Inserm, CNRS, BioMaps, 91401 Orsay, France
| | - Quentin Béen
- Nancyclotep, Molecular Imaging Platform, 54500 Vandoeuvre-les-Nancy, France
| | | | - Bertrand Kuhnast
- Université Paris Saclay, CEA Inserm, CNRS, BioMaps, 91401 Orsay, France
| | - Charlotte Collet-Defossez
- Nancyclotep, Molecular Imaging Platform, 54500 Vandoeuvre-les-Nancy, France
- Université de Lorraine, Inserm, IADI, 54000 Nancy, France
| |
Collapse
|
2
|
Ajalin RM, Al-Abdulrasul H, Tuisku JM, Hirvonen JES, Vahlberg T, Lahdenpohja S, Rinne JO, Brück AE. Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [ 18 F]FMPEP-d 2. Mov Disord 2022; 37:1673-1682. [PMID: 35674270 PMCID: PMC9544132 DOI: 10.1002/mds.29117] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 04/21/2022] [Accepted: 05/13/2022] [Indexed: 11/10/2022] Open
Abstract
Background The endocannabinoid system is a widespread neuromodulatory system affecting several biological functions and processes. High densities of type 1 cannabinoid (CB1) receptors and endocannabinoids are found in basal ganglia, which makes them an interesting target group for drug development in basal ganglia disorders such as Parkinson's disease (PD). Objective The aim of this study was to investigate CB1 receptors in PD with [18F]FMPEP‐d2 positron emission tomography (PET) and the effect of dopaminergic medication on the [18F]FMPEP‐d2 binding. Methods The data consisted of 16 subjects with PD and 10 healthy control subjects (HCs). All participants underwent a [18F]FMPEP‐d2 high‐resolution research tomograph PET examination for the quantitative assessment of cerebral binding to CB1 receptors. To investigate the effect of dopaminergic medication on the [18F]FMPEP‐d2 binding, 15 subjects with PD underwent [18F]FMPEP‐d2 PET twice, both on and off antiparkinsonian medication. Results [18F]FMPEP‐d2 distribution volume was significantly lower in the off scan compared with the on scan in basal ganglia, thalamus, hippocampus, and amygdala (P < 0.05). Distribution volume was lower in subjects with PD off than in HCs globally (P < 0.05), but not higher than in HCs in any brain region. Conclusions Subjects with PD have lower CB1 receptor availability compared with HCs. PD medication increases CB1 receptor toward normal levels. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Collapse
Affiliation(s)
- Riikka M Ajalin
- Turku PET Centre, Turku University and Turku University Hospital, Turku, Finland.,Neurocenter, Turku University Hospital and Clinical Neurosciences, University of Turku, Turku, Finland
| | - Haidar Al-Abdulrasul
- Turku PET Centre, Turku University and Turku University Hospital, Turku, Finland.,Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland
| | - Jouni M Tuisku
- Turku PET Centre, Turku University and Turku University Hospital, Turku, Finland
| | - Jussi E S Hirvonen
- Turku PET Centre, Turku University and Turku University Hospital, Turku, Finland.,Department of Radiology, University of Turku and Turku University Hospital, Turku, Finland
| | - Tero Vahlberg
- Department of Biostatistics, University of Turku, Turku, Finland
| | - Salla Lahdenpohja
- Turku PET Centre, Turku University and Turku University Hospital, Turku, Finland
| | - Juha O Rinne
- Turku PET Centre, Turku University and Turku University Hospital, Turku, Finland.,Neurocenter, Turku University Hospital and Clinical Neurosciences, University of Turku, Turku, Finland
| | - Anna E Brück
- Turku PET Centre, Turku University and Turku University Hospital, Turku, Finland.,Neurocenter, Turku University Hospital and Clinical Neurosciences, University of Turku, Turku, Finland
| |
Collapse
|
3
|
Lahdenpohja S, Rajala N, Kirjavainen A, Haaparanta-Solin M, Solin O. Quantitation of a CB1R tracer [18F]FPATPP with radioLC/MS/MS. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00366-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Rajala N, Lahdenpohja S, Kirjavainen A. Improved synthesis of [18F]FPATPP via Ru-mediated 18F-Fluorination. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00294-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Tolvanen T, Kalliokoski K, Malaspina S, Kuisma A, Lahdenpohja S, Postema EJ, Miller MP, Scheinin M. Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers. J Nucl Med 2021; 62:679-684. [PMID: 33067338 PMCID: PMC8844263 DOI: 10.2967/jnumed.120.252114] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 09/16/2020] [Indexed: 12/12/2022] Open
Abstract
This first-in-humans study investigated the safety, biodistribution, and radiation dosimetry of a novel 18F-labeled radiohybrid prostate-specific membrane antigen (rhPSMA) PET imaging agent, 18F-rhPSMA-7.3. Methods: Six healthy volunteers (3 men, 3 women) underwent multiple whole-body PET acquisitions at scheduled time points up to 248 min after the administration of 18F-rhPSMA-7.3 (mean activity, 220; range, 210–228 MBq). PET scans were conducted in 3 separate sessions, and subjects were encouraged to void between sessions. Blood and urine samples were collected for up to 4 h after injection to assess metabolite-corrected radioactivity in whole blood, plasma, and urine. Quantitative measurements of 18F radioactivity in volumes of interest over target organs were determined directly from the PET images at 8 time points, and normalized time–activity concentration curves were generated. These normalized cumulated activities were then inputted into the OLINDA/EXM package to calculate the internal radiation dosimetry and the subjects’ effective dose. Results:18F-rhPSMA-7.3 was well tolerated. One adverse event (mild headache, not requiring medication) was considered possibly related to 18F-rhPSMA-7.3. The calculated effective dose was 0.0141 mSv/MBq when using a 3.5-h voiding interval. The organs with the highest mean absorbed dose per unit of administered radioactivity were the adrenals (0.1835 mSv/MBq), the kidneys (0.1722 mSv/MBq), the submandibular glands (0.1479 mSv), and the parotid glands (0.1137 mSv/MBq). At the end of the first scanning session (mean time, 111 min after injection), an average of 7.2% (range, 4.4%–9.0%) of the injected radioactivity of 18F-rhPSMA-7.3 was excreted into urine. Conclusion: The safety, biodistribution, and internal radiation dosimetry of 18F-rhPSMA-7.3 are considered favorable for PET imaging.
Collapse
Affiliation(s)
- Tuula Tolvanen
- Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
| | - Kari Kalliokoski
- Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
| | - Simona Malaspina
- Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
| | - Anna Kuisma
- Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.,Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
| | - Salla Lahdenpohja
- Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
| | | | | | - Mika Scheinin
- Clinical Research Services Turku-CRST Ltd., Turku, Finland
| |
Collapse
|
6
|
Lahdenpohja S, Huuskonen P, Rajala N, Kirjavainen A. Synthesis of [18F]FPATPP via Cu-mediated 18F-fluorination. Nucl Med Biol 2021. [DOI: 10.1016/s0969-8051(21)00384-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Lahdenpohja S, Rajala NA, Helin JS, Haaparanta-Solin M, Solin O, López-Picón FR, Kirjavainen AK. Ruthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB 1 Receptor Imaging Agent [ 18F]FPATPP. ACS Chem Neurosci 2020; 11:2009-2018. [PMID: 32479723 PMCID: PMC7497626 DOI: 10.1021/acschemneuro.0c00313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
![]()
Cannabinoid receptor
1 (CB1R) controls various physiological and pathological conditions,
including memory, motivation, and inflammation, and is thus an interesting
target for positron emission tomography (PET). Herein, we report a
ruthenium-mediated radiolabeling synthesis and preclinical evaluation
of a new CB1R specific radiotracer, [18F]FPATPP. [18F]FPATPP was produced with 16.7 ± 5.7% decay-corrected
radiochemical yield and >95 GBq/μmol molar activity. The
tracer showed high stability, low defluorination, and high specific
binding to CB1Rs in mouse brain.
Collapse
Affiliation(s)
- Salla Lahdenpohja
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Noora A. Rajala
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Jatta S. Helin
- Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland
- MediCity Research Laboratory, University of Turku, Turku, Finland
| | - Merja Haaparanta-Solin
- Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland
- MediCity Research Laboratory, University of Turku, Turku, Finland
| | - Olof Solin
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
- Accelerator Laboratory, Åbo Akademi University, Turku, Finland
- Department of Chemistry, University of Turku, Turku, Finland
| | - Francisco R. López-Picón
- Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland
- MediCity Research Laboratory, University of Turku, Turku, Finland
| | - Anna K. Kirjavainen
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| |
Collapse
|
8
|
Lahdenpohja S, Keller T, Forsback S, Viljanen T, Kokkomäki E, Kivelä RV, Bergman J, Solin O, Kirjavainen AK. Automated GMP production and long-term experience in radiosynthesis of CB 1 tracer [ 18 F]FMPEP-d 2. J Labelled Comp Radiopharm 2020; 63:408-418. [PMID: 32374481 DOI: 10.1002/jlcr.3845] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 03/31/2020] [Accepted: 04/28/2020] [Indexed: 11/11/2022]
Abstract
Here, we describe the development of an in-house-built device for the fully automated multistep synthesis of the cannabinoid CB1 receptor imaging tracer (3R,5R)-5-(3-([18 F]fluoromethoxy-d2 )phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one ([18 F]FMPEP-d2 ), following good manufacturing practices. The device is interfaced to a HPLC and a sterile filtration unit in a clean room hot cell. The synthesis involves the nucleophilic 18 F-fluorination of an alkylating agent and its GC purification, the subsequent 18 F-fluoroalkylation of a precursor molecule, the semipreparative HPLC purification of the 18 F-fluoroalkylated product, and its formulation for injection. We have optimized the duration and temperature of the 18 F-fluoroalkylation reaction and addressed the radiochemical stability of the formulated product. During the past 5 years (2013-2018), we have performed a total of 149 syntheses for clinical use with a 90% success rate. The activity yield of the formulated product has been 1.0 ± 0.4 GBq starting from 11 ± 2 GBq and the molar activity 600 ± 300 GBq/μmol at the end of synthesis.
Collapse
Affiliation(s)
- Salla Lahdenpohja
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Thomas Keller
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Sarita Forsback
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland.,Department of Chemistry, University of Turku, Turku, Finland
| | - Tapio Viljanen
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Esa Kokkomäki
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Riikka V Kivelä
- Hospital Pharmacy, Turku University Hospital, Turku, Finland
| | - Jörgen Bergman
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Olof Solin
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland.,Department of Chemistry, University of Turku, Turku, Finland.,Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, Finland
| | - Anna K Kirjavainen
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| |
Collapse
|
9
|
Lahdenpohja S, Keller T, Rajander J, Kirjavainen AK. Radiosynthesis of the norepinephrine transporter tracer [ 18 F]NS12137 via copper-mediated 18 F-labelling. J Labelled Comp Radiopharm 2019; 62:259-264. [PMID: 30843249 PMCID: PMC6619244 DOI: 10.1002/jlcr.3717] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Revised: 02/18/2019] [Accepted: 02/25/2019] [Indexed: 12/12/2022]
Abstract
[18F]NS12137 (exo‐3‐[(6‐[18F]fluoro‐2‐pyridyl)oxy]8‐azabicyclo[3.2.1]octane) is a highly selective norepinephrine transporter (NET) tracer. NETs are responsible for the reuptake of norepinephrine and dopamine and are linked to several neurodegenerative and neuropsychiatric disorders. The aim of this study was to develop a copper‐mediated 18F‐fluorination method for the production of [18F]NS12137 with straightforward synthesis conditions and high radiochemical yield and molar activity. [18F]NS12137 was produced in two steps. Radiofluorination of [18F]NS12137 was performed via a copper‐mediated pathway starting with a stannane precursor and using [18F]F− as the source of the fluorine‐18 isotope. Deprotection was performed via acid hydrolysis. The radiofluorination reaction was nearly quantitative as was the deprotection based on HPLC analysis. The radiochemical yield of the synthesis was 15.1 ± 0.5%. Molar activity of [18F]NS12137 was up to 300 GBq/μmol. The synthesis procedure is straightforward and can easily be automated and adapted for clinical production.
Collapse
Affiliation(s)
- Salla Lahdenpohja
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Thomas Keller
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| | - Johan Rajander
- Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, Finland
| | - Anna K Kirjavainen
- Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
| |
Collapse
|
10
|
Lahesmaa M, Eriksson O, Gnad T, Oikonen V, Bucci M, Hirvonen J, Koskensalo K, Teuho J, Niemi T, Taittonen M, Lahdenpohja S, U Din M, Haaparanta-Solin M, Pfeifer A, Virtanen KA, Nuutila P. Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue. Diabetes 2018; 67:1226-1236. [PMID: 29650773 DOI: 10.2337/db17-1366] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Accepted: 04/02/2018] [Indexed: 11/13/2022]
Abstract
Activating brown adipose tissue (BAT) could provide a potential approach for the treatment of obesity and metabolic disease in humans. Obesity is associated with upregulation of the endocannabinoid system, and blocking the cannabinoid type 1 receptor (CB1R) has been shown to cause weight loss and to decrease cardiometabolic risk factors. These effects may be mediated partly via increased BAT metabolism, since there is evidence that CB1R antagonism activates BAT in rodents. To investigate the significance of CB1R in BAT function, we quantified the density of CB1R in human and rodent BAT using the positron emission tomography radioligand [18F]FMPEP-d2 and measured BAT activation in parallel with the glucose analog [18F]fluorodeoxyglucose. Activation by cold exposure markedly increased CB1R density and glucose uptake in the BAT of lean men. Similarly, β3-receptor agonism increased CB1R density in the BAT of rats. In contrast, overweight men with reduced BAT activity exhibited decreased CB1R in BAT, reflecting impaired endocannabinoid regulation. Image-guided biopsies confirmed CB1R mRNA expression in human BAT. Furthermore, CB1R blockade increased glucose uptake and lipolysis of brown adipocytes. Our results highlight that CB1Rs are significant for human BAT activity, and the CB1Rs provide a novel therapeutic target for BAT activation in humans.
Collapse
Affiliation(s)
- Minna Lahesmaa
- Turku PET Centre, University of Turku, Turku, Finland
- Turku PET Centre, Turku University Hospital, Turku, Finland
| | - Olof Eriksson
- Turku PET Centre, Åbo Akademi, Turku, Finland
- Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
| | - Thorsten Gnad
- Institute of Pharmacology and Toxicology, University of Bonn, Bonn, Germany
| | - Vesa Oikonen
- Turku PET Centre, University of Turku, Turku, Finland
| | - Marco Bucci
- Turku PET Centre, University of Turku, Turku, Finland
| | - Jussi Hirvonen
- Turku PET Centre, University of Turku, Turku, Finland
- Department of Radiology, University of Turku, Turku, Finland
| | - Kalle Koskensalo
- Turku PET Centre, University of Turku, Turku, Finland
- Turku PET Centre, Turku University Hospital, Turku, Finland
| | - Jarmo Teuho
- Turku PET Centre, Turku University Hospital, Turku, Finland
| | - Tarja Niemi
- Department of Plastic and General Surgery, Turku University Hospital, Turku, Finland
| | - Markku Taittonen
- Department of Anesthesiology, Turku University Hospital, Turku, Finland
| | | | - Mueez U Din
- Turku PET Centre, University of Turku, Turku, Finland
| | - Merja Haaparanta-Solin
- Turku PET Centre, University of Turku, Turku, Finland
- MediCity Research Laboratories, University of Turku, Turku, Finland
| | - Alexander Pfeifer
- Institute of Pharmacology and Toxicology, University of Bonn, Bonn, Germany
| | - Kirsi A Virtanen
- Turku PET Centre, University of Turku, Turku, Finland
- Turku PET Centre, Turku University Hospital, Turku, Finland
| | - Pirjo Nuutila
- Turku PET Centre, University of Turku, Turku, Finland
- Department of Endocrinology, Turku University Hospital, Turku, Finland
| |
Collapse
|
11
|
Krzyczmonik A, Keller T, Kirjavainen AK, Lahdenpohja S, Forsback S, Solin O. Use of SF 6 for the production of electrophilic 18 F-fluorination reagents. J Fluor Chem 2017. [DOI: 10.1016/j.jfluchem.2017.10.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|